Literature DB >> 19801542

Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis.

Youngkyun Lee1, Jeongim Ha, Hyung Joon Kim, Yeun-Soo Kim, Eun-Ju Chang, Woo-Joo Song, Hong-Hee Kim.   

Abstract

DYRK1A is a serine/threonine kinase that has been linked to mental retardation associated with Down syndrome. In the present report, we describe a previously unknown role for DYRK1A in bone homeostasis. The protein expression of DYRK1A increased during osteoclast differentiation. In vitro studies in osteoclasts revealed that DYRK1A inhibited osteoclastogenesis. Whereas DYRK1A phosphorylated and inhibited the osteoclastogenic transcription factor NFATc1, forced expression of NFATc1 induced DYRK1A expression, suggesting a negative feedback loop. Transgenic mice overexpressing DYRK1A by the extent of the increased gene dosage in Down syndrome exhibited significantly reduced bone mass despite the decreased osteoclastogenesis, which is reminiscent of osteoporotic bone phenotype in Down syndrome patients. In these mice, attenuated osteoblast differentiation and function in the presence of extra DYRK1A overrode the effect of impaired osteoclastogenesis. However, impeded osteoclastogenesis in DYRK1A transgenic mice was proven to be beneficial in protecting bone loss induced by inflammation or estrogen deficiency. These results provide novel insight into the role for DYRK1A in bone homeostasis as well as in bone destructive diseases, in which modulation of DYRK1A might be used as a strategy to treat unregulated bone resorption.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801542      PMCID: PMC2785177          DOI: 10.1074/jbc.M109.042234

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Histological assessment of vertebral bone in a Down's syndrome adult with osteoporosis.

Authors:  J S Grimwood; A Kumar; D R Bickerstaff; S K Suvarna
Journal:  Histopathology       Date:  2000-03       Impact factor: 5.087

2.  Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice.

Authors:  J T Richtsmeier; L L Baxter; R H Reeves
Journal:  Dev Dyn       Date:  2000-02       Impact factor: 3.780

3.  Bone mass, gonadal function and biochemical assessment in young men with trisomy 21.

Authors:  Athanasios Sakadamis; Nickoletta Angelopoulou; Chrysoula Matziari; Vasilios Papameletiou; Vasilios Souftas
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2002-01-10       Impact factor: 2.435

4.  Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome.

Authors:  Joan T Richtsmeier; Ann Zumwalt; Elaine J Carlson; Charles J Epstein; Roger H Reeves
Journal:  Am J Med Genet       Date:  2002-02-01

5.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.

Authors:  X Altafaj; M Dierssen; C Baamonde; E Martí; J Visa; J Guimerà; M Oset; J R González; J Flórez; C Fillat; X Estivill
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

6.  Bone mineral density and muscle strength in young men with mental retardation (with and without Down syndrome).

Authors:  N Angelopoulou; C Matziari; V Tsimaras; A Sakadamis; V Souftas; K Mandroukas
Journal:  Calcif Tissue Int       Date:  2000-03       Impact factor: 4.333

Review 7.  RANK-L and RANK: T cells, bone loss, and mammalian evolution.

Authors:  Lars E Theill; William J Boyle; Josef M Penninger
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 8.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 9.  Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.

Authors:  Zang Hee Lee; Hong Hee Kim
Journal:  Biochem Biophys Res Commun       Date:  2003-05-30       Impact factor: 3.575

10.  Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption.

Authors:  Eun-Ju Chang; Jeongim Ha; Frank Oerlemans; You Jin Lee; Soo Woong Lee; Jiyoon Ryu; Hyung Joon Kim; Youngkyun Lee; Hyun-Man Kim; Je-Yong Choi; Jin Young Kim; Chan Soo Shin; Youngmi Kim Pak; Sakae Tanaka; Bé Wieringa; Zang Hee Lee; Hong-Hee Kim
Journal:  Nat Med       Date:  2008-09       Impact factor: 53.440

View more
  24 in total

1.  Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.

Authors:  Joshua D Blazek; Anna Gaddy; Rachel Meyer; Randall J Roper; Jiliang Li
Journal:  Bone       Date:  2010-09-24       Impact factor: 4.398

2.  Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.

Authors:  J H Kang; H M Ko; J S Moon; H I Yoo; J Y Jung; M S Kim; J T Koh; W J Kim; S H Kim
Journal:  J Dent Res       Date:  2014-09-25       Impact factor: 6.116

3.  DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.

Authors:  Jianling Ji; Hane Lee; Bob Argiropoulos; Naghmeh Dorrani; John Mann; Julian A Martinez-Agosto; Natalia Gomez-Ospina; Natalie Gallant; Jonathan A Bernstein; Louanne Hudgins; Leah Slattery; Bertrand Isidor; Cédric Le Caignec; Albert David; Ewa Obersztyn; Barbara Wiśniowiecka-Kowalnik; Michelle Fox; Joshua L Deignan; Eric Vilain; Emily Hendricks; Margaret Horton Harr; Sarah E Noon; Jessi R Jackson; Alisha Wilkens; Ghayda Mirzaa; Noriko Salamon; Jeff Abramson; Elaine H Zackai; Ian Krantz; A Micheil Innes; Stanley F Nelson; Wayne W Grody; Fabiola Quintero-Rivera
Journal:  Eur J Hum Genet       Date:  2015-05-06       Impact factor: 4.246

Review 4.  Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis.

Authors:  G Paolo Dotto
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

5.  Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.

Authors:  Samantha D McElyea; John M Starbuck; Danika M Tumbleson-Brink; Emily Harrington; Joshua D Blazek; Ahmed Ghoneima; Katherine Kula; Randall J Roper
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

6.  Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.

Authors:  Irushi Abeysekera; Jared Thomas; Taxiarchis M Georgiadis; Alycia G Berman; Max A Hammond; Karl J Dria; Joseph M Wallace; Randall J Roper
Journal:  Mol Nutr Food Res       Date:  2016-02-11       Impact factor: 5.914

7.  Commonality in Down and fetal alcohol syndromes.

Authors:  Jeffrey P Solzak; Yun Liang; Feng C Zhou; Randall J Roper
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-04-03

Review 8.  Skeletal dynamics of Down syndrome: A developing perspective.

Authors:  Jonathan M LaCombe; Randall J Roper
Journal:  Bone       Date:  2019-12-27       Impact factor: 4.398

9.  DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway.

Authors:  Joo-Young Im; Bo-Kyung Kim; Sung-Hoon Yoon; Byoung Chul Cho; Yu Mi Baek; Mi-Jung Kang; Nayeon Kim; Young-Dae Gong; Misun Won
Journal:  Exp Mol Med       Date:  2021-04-15       Impact factor: 8.718

10.  Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.

Authors:  Meera Soundararajan; Annette K Roos; Pavel Savitsky; Panagis Filippakopoulos; Arminja N Kettenbach; Jesper V Olsen; Scott A Gerber; Jeyanthy Eswaran; Stefan Knapp; Jonathan M Elkins
Journal:  Structure       Date:  2013-05-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.